Is estimated exposure an accurate surrogate for measured fludarabine levels in patients with CAR T-cell therapy?

Related Experiment Video

Updated: Jun 21, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.4K

Mario Andrés Sánchez-Salinas1,2, Marta Miarons3,4, Iñaki F Troconiz5

  • 1Department of Hematology, Vall d'Hebron University Hospital, Experimental Hematology, Vall d'Hebron Institute of Oncology, Barcelona, Spain.

Blood Advances
|January 17, 2024
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.1K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.4K

Related Experiment Videos

Last Updated: Jun 21, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.4K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.1K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.4K

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Articles linked to this work by shared authors, journal, and citation graph.

CAR T-cell activity for autoimmune diseases across EBMT centers: an international survey on behalf of the Autoimmune Diseases Working Party and the Cellular Therapy and Immunobiology Working Party.

Haematologica·2026

Bridging therapy in pediatric and AYA patients under 25 years with relapsed/refractory B-ALL undergoing anti-CD19 CAR-T therapy: a multicenter retrospective study by the Spanish group GETH-TC.

Bone marrow transplantation·2026

Clinical Features and Outcomes of Therapy-Related Myeloid Neoplasms After CAR T-Cell Therapy.

Blood advances·2026

Immunotherapy refractoriness and early post-alloHCT relapse define ultra-high-risk B-ALL after CD19 CAR T-cell therapy.

Blood advances·2026

Timing of Allogeneic Hematopoietic Cell Transplantation after Inotuzumab Ozogamicin Influences Sinusoidal Obstruction Syndrome and Survival in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia.

Transplantation and cellular therapy·2026

Comprehensive analysis of prognostic factors in myelodysplastic syndromes with isolated deletion of chromosome 5q.

Blood advances·2026

Omission of Radiation Therapy is Associated with Inferior Disease Control in High Risk Early-Stage Hodgkin Lymphoma.

Blood advances·2026

Impact of initial dosing and subsequent dose reduction of zanubrutinib in patients with Waldenström macroglobulinemia.

Blood advances·2026

Reduced-Intensity Haploidentical Bone Marrow Transplantation in Children with Severe Sickle Cell Disease: BMT CTN 1507.

Blood advances·2026

CAR T-cell therapy referral patterns and utilization for relapsed/refractory large B-cell lymphoma in the United States.

Blood advances·2026

Effects of post-transplant cyclophosphamide on immune reconstitution after haploidentical and HLA-matched transplant.

Blood advances·2026

Adverse impact of deletion of the chromosome 6 on clinical outcomes after allogeneic hematopoietic transplantation.

Blood advances·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us